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Major progress in cancer immunotherapies have been obtained by the use of tumor tar-
geting strategies, in particular with the development of bi-functional fusion proteins such 
as ImmTacs or BiTes, which engage effector T cells for targeted elimination of tumor cells. 
Given the significance of invariant natural killer T (iNKT) cells in bridging innate and adaptive 
immunity, we have developed a bi-functional protein composed of the extracellular part of 
CD1d molecule that was genetically fused to an scFv fragment from high affinity antibod-
ies against HER2 or CEA. Systemic treatments with the CD1d-antitumor fusion proteins 
loaded with the agonist alpha-galactosylceramide (αGalCer) led to specific iNKT cell acti-
vation, resulting in a sustained growth inhibition of established tumors expressing HER2 
or CEA, while treatment with the free αGalCer was ineffective. Importantly, we discovered 
that αGalCer/CD1d-antitumor fusion proteins were able to maintain iNKT cells reactive to 
multiple re-stimulations in contrast to their anergic state induced after a single injection 
of free αGalCer. We further demonstrated that the antitumor effects by αGalCer/CD1d-
antitumor fusion proteins were largely dependent on the iNKT cell-mediated transactivation 
of NK cells. Moreover, prolonged antitumor effects could be obtained when combining the 
CD1d-antitumor fusion protein treatment with a therapeutic peptide/CpG cancer vaccine, 
which favored the capacity of iNKT cells to transactivate cross-presenting DCs for efficient 
priming of tumor-specific CD8 T cells. We will also summarize these pre-clinical results 
with a special focus on the cellular mechanisms underlying iNKT cell unresponsiveness to 
antigen re-challenge. Finally, we will discuss the perspectives regarding iNKT cell-medi-
ated tumor targeting strategy in cancer immunotherapy.
Keywords: bi-functional fusion protein, CD1d-antitumor scFv, nKT  cell, DC activation, innate and adaptive 
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HARneSSinG inKT CeLLS FOR CAnCeR iMMUnOTHeRAPY
Invariant natural killer T (iNKT) cells represent a unique T cell subset characterized by an invariant 
TCR alpha chain paired with a restricted number of TCR beta chains both in mouse and humans 
(1–3). iNKT  cells have the capacity to bridge the innate and adaptive immunity (1, 4–6). First, 
iNKT cells acquire an effector memory phenotype before birth, which allows their trafficking to 
the site of inflammation where they exhibit direct cytotoxic capacity by the expression of perforin 
and granzymes. Second, iNKT cells secrete large amounts of effector cytokines very rapidly after 
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activation and are potent activators of NK  cells through their 
fast release of IFNγ. Third, activated iNKT  cells communicate 
with DCs via the upregulation of CD40L which promotes DCs 
licensing and maturation, and subsequently effective CD8 T cell 
responses (7, 8).
The significance of iNKT  cells in antitumor immunity has 
been well studied in both mouse models and clinics (1, 4, 5, 
9–12). Mice lacking iNKT cells are more prone to chemical or 
p53 loss-induced tumor development (13–15). Along the same 
line, late-stage cancer patients harbor either decreased numbers 
of iNKT cells or iNKT cells showing certain functional deficien-
cies (11, 16–19). Also, head and neck squamous cell carcinoma 
(HNSCC) patients with lower levels of circulating iNKT  cells 
before radiation therapy show poor 3-year survival as compared 
to patients harboring higher circulating levels of iNKT cells (20). 
These observations have triggered the development of iNKT-
mediated cancer immunotherapy mainly by the use of the CD1d 
agonist ligand alpha-galactosylceramide (αGalCer), either as 
a free drug or loaded on DCs before their adoptive transfer, as 
reviewed by McEwen-Smith et al. (4) and Robertson et al. (21). 
These approaches have demonstrated potent iNKT cell activation 
and subsequent NK cell transactivation and CD8 T cell priming. 
Despite the potent tumor cytotoxicity and transactivating proper-
ties of iNKT cells, clinical responses have remained so far limited, 
resulting on the one hand from the small numbers of iNKT cells, 
and on the other hand from their short-lived activation followed 
by long-term unresponsiveness. To address the issue of the small 
iNKT cell numbers, the adoptive cell transfer (ACT) of ex vivo 
expanded autologous iNKT cells has been tested in HNSCC and 
melanoma patients with, respectively, some objective clinical 
responses and Th1 responses, in particular when iNKT  cells 
were inoculated in the vicinity of the tumor in combination with 
αGalCer-pulsed DCs (22–24). As mentioned above, the powerful 
initial αGalCer-mediated activation of iNKT cells is followed by 
long-term unresponsiveness which is another drawback for the 
therapeutic manipulation of iNKT  cells against cancer (9, 25, 
26). In this regard, ACT of αGalCer-pulsed DCs was reported 
to trigger more effective antitumor immunity than administra-
tion of free αGalCer in mouse experimental models and cancer 
patients (25–28).
More recently, ACT of human iNKT cells transduced with a 
chimeric antigen receptor (CAR) was reported as a novel and safe 
platform in a humanized mouse tumor model (29). This attractive 
approach that requires further validation in immunocompetent 
hosts would combine the ACT of high numbers of tumor-specific 
iNKT cells which could be co-activated by αGalCer treatment. 
However, CAR-T  cell immunotherapy represents an expensive 
personalized cancer treatment and alternative cost-effective 
treatments would be preferred, such as the development of solu-
ble molecules able to activate and redirect endogenous iNKT cells 
to the tumor site.
TUMOR TARGeTinG in CAnCeR 
iMMUnOTHeRAPieS
Major progress in cancer therapy have been obtained by the 
development of tumor targeting strategies, which mostly 
involve monoclonal antibodies (mAbs) specific either of 
tumor-associated antigens (TAA), or soluble factors released by 
the tumor or inhibitory and activatory receptors expressed by 
tumor-infiltrating T cells (TILs). For instance, numerous clinical 
protocols are now routinely involving tumor targeting antibod-
ies such as anti-CD19, anti-HER2, or anti-EGFR combined 
with chemotherapy or kinase inhibitors for the treatment of, 
respectively, B cell lymphoma, breast, gastric, and colon cancers 
(30, 31). In addition to the use of native mAbs, various antibody 
formats have been developed, which allowed, for instance, the 
development of a large array of bi-functional molecules by the 
genetic fusion of an antibody fragment with an effector mol-
ecule, such as another antibody fragment, a toxin, a cytokine, 
or an antigen-presenting molecule. Yet, even a large array of 
bi-functional proteins have been tested in pre-clinical studies 
and some clinical trials, very few have so far entered routine 
clinical application. Among the few bi-functional molecules 
that are currently under clinical testing, the most promising are 
the Bi-specific T cell engagers or BiTes, which directly activate 
T cells against tumor cells by combining an anti-CD3 scFv frag-
ment with another scFv specific of an antigen over-expressed 
on tumor cells (32). The second class of bi-functional molecules 
that are currently tested in metastatic melanoma patients are the 
so-called ImmTACs for “immune mobilizing monoclonal TCRs 
against cancer,” which combines an optimized TCR specific of 
HLA-A2/gp100 (IMCgp100) fused to an anti-CD3 scFv (33). 
While the use of BiTes is restricted to surface-expressed tumor 
antigens, ImmTACs have the potential to target endogenously 
processed antigens loaded on MHC I molecules, which greatly 
increases the possible applications. However, ImmTACs require 
TCR optimization in the context of defined HLA haplotypes, 
which represents a personalized and expensive approach. By 
contrast, BiTes have the advantage to be one drug which fits 
all patients. Along the same line, we and others have initially 
developed bi-functional molecules, which combine an MHC 
I molecule with an antitumor antibody fragment (34–37). We 
could demonstrate the capacity of these bi-functional mole cules 
to redirect tumor-specific T cells to the tumor site, which led to 
a significant inhibition of tumor growth (34, 35). More recently, 
we developed CD1d-antitumor fusion proteins, which offered 
two main advantages. First, CD1d bi-functional molecules are 
exploiting a monomorphic antigen-presenting molecule that 
would fit all patients. Second, when loaded with αGalCer, these 
CD1d-antitumor fusion proteins will specifically activate Type 1 
iNKT cells and redirect both the innate and the adaptive antitu-
mor responses to the tumor site, in view of the transactivating 
properties of iNKT cells.
CD1d-AnTiTUMOR FUSiOn PROTeinS
In order to redirect iNKT  cell immunity at the tumor site, 
we have developed CD1d molecules genetically fused to an 
antibody scFv fragment specific of the HER2 or CEA antigens, 
which are overexpressed in several cancers (9, 10). Briefly, 
mouse β2-microglobulin coding sequence (β2M) was fused to 
the soluble part of CD1d followed by the antibody scFv frag-
ment and a 6xHIS-tag for purification. Flexible glycine/serine 
FiGURe 1 | Alpha-galactosylceramide (αGalCer)/CD1d-antibody fusion proteins redirect invariant natural killer T (iNKT), NK, and T cell immunity to solid tumors 
and promote prolonged therapeutic responses. Tumor microenvironment: Step 1: systemic treatments with the αGalCer/CD1d-antitumor fusion protein lead to 
its binding to the tumor-associated antigen at the tumor site. Step 2: tumor-bound αGalCer/CD1d-antitumor fusion proteins lead to specific activation of 
iNKT cells. Step 3: rapid iNKT-mediated transactivation of NK cells and DCs, which then activate and recruit T cells. Step 4: release of IFNγ and cytotoxic 
molecules from NK and CD8 T cells that mediate targeted tumor destruction. Periphery: soluble αGalCer/CD1d fused or not to an antitumor scFv antibody 
fragment can also activate iNKT cells in peripheral lymphoid and non-lymphoid organs. The underlying mechanisms for this extra-tumoral activation of iNKT cells 
remain unclear.
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linkers were inserted after β2M, CD1d, and scFv to facilitate 
proper folding. Recombinant proteins were produced in 293-
EBNA cells. Strikingly, unlike MHC I/peptide monomer and 
conventional CD8 T  cells, αGalCer/CD1d monomers were 
able to activate iNKT cells in vivo as seen by iNKT TCR down-
modulation, as well as iNKT and NK cell proliferation and DC 
maturation (9). The iNKT cell activation by CD1d monomers 
may result from the significantly higher binding affinity of the 
iNKT TCR for αGalCer/CD1d (KD ~ 0.3 μM) (38), as compared 
to conventional TCR for MHC/peptide (KD range 1–50  µM) 
(39). Moreover, it is possible that in vivo aggregation or loose 
cell binding may also facilitate iNKT cell monomer activation. 
Nonetheless, significant antitumor activity only occurred when 
the CD1d protein was targeted to a tumor antigen by its fusion 
to an antibody scFv fragment. First, we demonstrated that 
B16-HER2 tumor cells pre-coated with αGalCer/CD1d-anti-
HER2 fusion proteins totally abolished their potency to initiate 
tumors (9). In view of these encouraging results, we tested the 
therapeutic efficacy of αGalCer/CD1d-anti-HER2 proteins in 
mice bearing established B16-HER2 lung tumor nodules or 
subcutaneous tumors. In both models, we could demonstrate 
a significant inhibition of tumor growth, which was dependent 
on the presence of iNKT and NK cells as the antitumor effects 
were abolished in CD1d-deficient mice or upon depletion of 
NK cells (9). The analysis of peripheral lymphoid organs and 
tumor tissue revealed (i) localization of CD1d-antitumor 
proteins at the tumor site, (ii) recruitment of iNKT, NK, and 
T cells at the tumor, (iii) sustained activation of iNKT cells, and 
(iv) adjuvant effect on CD8 T cell priming (as depicted in the 
Figure 1).
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Localization of CD1d-Antitumor Proteins 
at the Tumor Site
CD1d-antitumor proteins were initially validated in  vitro for 
their specific binding to tumor cells expressing the relevant 
tumor antigen. Next, we investigated whether intravenously 
injected fusion proteins would reach the tumor site in sufficient 
amounts to attract iNKT cells. Indeed, when injecting radiola-
beled αGalCer/CD1d-anti-HER2 proteins in mice bearing on 
each flank either HER2-positive or HER2-negative tumors, up to 
twofold more radioactivity was found in HER2-positive tumors, 
as compared to HER2-negative tumors, while non-targeted 
αGalCer/CD1d protein did not localize preferentially to any of 
the tumors, although it induced systemic iNKT cell activation to 
some extent (9) (see Figure 1).
Recruitment of inKT, nK, and T Cells  
at the Tumor Site
When BrdU-positive iNKT cells in lung tumor nodules, there was 
a fivefold or twofold increase when compared to untreated mice or 
the ones treated with untargeted αGalCer/CD1d protein, respec-
tively. Most importantly, we observed a sevenfold enrichment of 
BrdU-positive NK cells and conventional T cells at tumor site, 
illustrating that the iNKT-mediated transactivation could trig-
ger their increased proliferation capacity. Interestingly, all three 
lymphocyte populations were instead decreased in the blood and 
spleen of CD1d-anti-HER2-treated animals as compared to the 
untargeted CD1d treatment, which might reflect their preferen-
tial recruitment to the tumor site upon HER2 targeting.
Sustained Activation of inKT Cells
Strikingly, iNKT cells remained reactive even after multiple treat-
ments with αGalCer/CD1d-antitumor fusion proteins, in contrast 
to the hyporesponsive state that typically follows the injection of 
the free ligand αGalCer. This preservation of iNKT cell respon-
siveness allowed multiple injections of the fusion proteins, which 
greatly enhanced antitumor efficacy of tumor-targeted CD1d as 
compared to αGalCer/CD1d molecules targeted to an irrelevant 
tumor antigen (10). Although iNKT cells remained substantially 
reactive to several injections of αGalCer/CD1d fusion proteins, 
we did observe a progressive loss of iNKT  cell activation with 
reduced cytokine production. It is highly possible that a propor-
tion of loaded glycolipid analog was lost from the fusion protein 
in vivo and, thus, processed by APCs, whereby they progressively 
induced iNKT cell anergy. In this regard, studies are in progress 
to assess the activities of CD1d fusion proteins loaded with 
photo-reactive αGalCer analogs that can be UV-crosslinked to 
CD1d. Initial studies show that complexes of mCD1d with a 
covalently bound αGalCer are resistant to dissociation and are 
potent iNKT cell activators in vitro and in vivo (personal com-
munication, S. Porcelli, Albert Einstein College of Medicine, 
NY, USA). The validation of these covalently bound αGalCer 
on CD1d antitumor fusion proteins is in progress with regard 
to their antitumor activity and capacity to maintain iNKT cells 
reactive to multiple stimulations.
The mechanism by which systemic treatments with αGalCer/
CD1d fusion proteins activate iNKT  cells without inducing 
anergy, as compared to free αGalCer analogs, remains an area 
of active exploration. High level of surface PD-1 expression 
has been well defined in exhausted CD8 T cells during chronic 
viral infection or tumor exposure, which closely correlated 
with T  cell functional decline (40). Likewise, PD-1 expression 
was also proposed to regulate iNKT  cell anergy induction 
(41, 42). Indeed, upregulation of PD-1 was observed shortly 
after αGalCer injections, which could last for at least 1  month 
(41). Moreover, two studies showed that blocking of the 
interaction between PD-1 and its ligand PD ligand 1 (PD-L1) 
or PD-L2 at the time of αGalCer injection could prevent the 
anergy induction of iNKT  cells (41, 42). In addition, injection 
of αGalCer into PD-1 deficient mice failed to induce iNKT cell 
anergy (42). In a different context, lymphocyte activation gene 3 
(LAG-3), another co-inhibitory molecule, was highly expressed 
on iNKT and NK  cells rather than conventional T  cells from 
chronically HIV-infected patients. Interestingly, LAG-3, but 
not PD-1, was associated with the reduced IFNγ production 
from iNKT cells, indicating that distinct mechanisms underly-
ing the anergy induction of iNKT  cells are context dependent 
(43). Yet, other mechanisms were also described (44, 45). For 
instance, deficiency of tuberous sclerosis 1 (TSC1), the upstream 
inhibitor of mTORC1 signaling, in iNKT cells results in increased 
resistance to αGalCer induced anergy, which is correlated with 
impaired upregulation of Egr2 and Grail (46). Altogether, 
it appears that PD-1 upregulation alone is not enough to mediate 
iNKT cell anergy.
Interestingly, a recent report showed that, instead of being aner-
gic, iNKT cells were rather reprogrammed toward a suppressive 
phenotype with the secretion of IL-10 associated with markedly 
reduced production of effector cytokines (47). Importantly, the 
study by Wingender et al. (48) showed that Th2-biased αGalCer 
analogs, which are less hydrophobic than Th1 analogs, are mostly 
surface-loaded as monomers on CD1d, resulting in a fast and 
transient iNKT cell activation which preserved their responsive-
ness to antigen re-challenge. By contrast, the more hydrophobic 
so-called Th1 αGalCer analogs characterized by a higher critical 
micelle concentration (CMC) are mostly loaded as micelles and 
internalized and processed on CD1d via the endosomal pathway, 
leading to a delayed and prolonged iNKT cell activation followed 
by long-term unresponsiveness (49, 50).
Therefore, we speculate that the surface loading of Th2 analogs 
on APCs is similar to the loading of αGalCer on CD1d fusion 
protein which in both cases triggers the fast and transient kinetic 
of iNKT cell activation, which might be instrumental for their 
retained reactivity to antigen re-challenge.
Adjuvant effect on CD8 T Cell Priming
CD1d-restricted iNKT  cells have been shown to promote 
the transactivation of DCs via the CD40L–CD40 interaction 
(see Figure  1), and their adjuvant properties on the adaptive 
immunity are well reported (51). For instance, DCs receive cognate 
“licensing” either from helper T cells or iNKT cells. With regard 
to iNKT cell, their licensing of cross-priming CD8α+ DCs induces 
them to produce CCL17, which thus attracts CCR4 expressing 
CD8 T cells (8). However, it remains largely undefined regarding 
how NK and T cells are recruited upon iNKT cell activation to the 
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tumor site. In this regard, several laboratories have developed vac-
cine strategies involving either the development of novel αGalCer 
analogs (52), αGalCer-loaded DC vaccines (53) or DC-targeted 
nanoparticles loaded with αGalCer (54). With regard to αGalCer/
CD1d proteins, repeated iNKT  cell activation by untargeted 
αGalCer/CD1d monomers efficiently promoted the maturation 
of pro-inflammatory DCs, while αGalCer as a free drug had only a 
marginal effect (9). Moreover, when tumor-bearing mice received 
an OVA peptide/CpG-ODN vaccination combined with systemic 
treatments of αGalCer/CD1d-antitumor fusion proteins, a syn-
ergistic expansion of OVA-specific CD8 T cells and NK cells was 
obtained, as compared to each regimen alone (12). The optimal 
adjuvant effect on innate and adaptive immune responses likely 
resulted from the enhanced production of the pro-inflammatory 
cytokine IL-12 by mature DCs, which was 10-fold higher with the 
combined stimuli of CpG-ODN and αGalCer/CD1d-anti-HER2 
fusion. Most importantly, the combined treatment resulted in an 
improved enrichment of tumor antigen-specific CD8 T cells and 
NK cells at the tumor site, associated with better tumor inhibition 
against tumors co-expressing HER2 and OVA (12). Interestingly, 
the antibody-mediated depletion of either NK cells or CD8 T cells, 
demonstrated an early and transient NK-mediated antitumor 
activity that was quickly replaced by the CD8 antitumor response. 
Thus, in this context, the direct antitumor activity of iNKT cells 
was minimal but was instead instrumental for the development of 
a tumor-targeted innate and adaptive antitumor responses.
PeRSPeCTiveS
CD1d-antitumor fusion proteins represent an attractive tool 
to redirect at the tumor site the immunoregulatory properties 
of iNKT  cells on the innate and adaptive immune responses. 
Importantly, this strategy holds the advantage to maintain 
iNKT cells reactive to multiple treatments in contrast to the use 
of an αGalCer analog as a free drug. Yet, the development of 
covalently bound αGalCer on CD1d fusion proteins will improve 
their stability in vivo and should greatly increase the sustained 
activation of iNKT cells and antitumor efficacy. Although, these 
molecules did not show significant liver toxicity, more in-depth 
pharmacological studies need to be done. Moreover, imaging 
techniques will help demonstrate that oligomerization of CD1d-
antitumor proteins on the tumor cell likely optimize the forma-
tion of an immunological synapse with the iNKT cell. However, 
in view of the low numbers of iNKT cells in cancer patients, the 
benefit would primarily result from their adjuvant effects rather 
than their direct antitumor cytotoxicity, unless iNKT ACT is 
included. Finally, CD1d is monomorphic and a single fusion 
protein would fit all patients, in contrast to other approaches such 
as ImmTacs, which involves individual TCRs.
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